Inflammatory response of ischemic tolerance in circulating plasma: preconditioning-induced by transient ischemic attack (TIA) phenomena in acute ischemia patients (AIS)

Introduction: Ischemic tolerance (IT) refers to a state where cells are resistant to the damaging effects caused by periods of ischemia. In a clinical scenario, the IT phenomenon would be activated by a recent transient ischemic attack (TIA) before an ischemic stroke (IS). The characterization of in...

Descripción completa

Detalles Bibliográficos
Autores: Colàs-Campàs, Laura, Farré, Joan, Mauri Capdevila, Gerard, Molina-Seguín, Jessica, Aymerich, Núria, Ois Santiago, Angel Javier, Roquer, Jaume, Tur, Silvia, García-Carreira, María Del Carmen, Martí-Fàbregas, Joan, Cruz-Culebras, Antonio, Segura, Tomás, Arqué, Gloria, Purroy, Francisco
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Institución:Universitat Pompeu Fabra
Repositorio:Repositorio Digital de la UPF
OAI Identifier:oai:repositori.upf.edu:10230/48031
Acceso en línea:http://hdl.handle.net/10230/48031
http://dx.doi.org/10.3389/fneur.2020.552470
Access Level:acceso abierto
Palabra clave:Biomarker (BM)
Endogenous neuroprotection
Ischemic preconditioning (IPC)
Ischemic stroke
Plasma
Transient ischemic attack (TIA)
Neuromuscular diseases care in the era of COVID-19
id ES_a3e9aafea4f548ccb7c6cd72fb2c530e
oai_identifier_str oai:repositori.upf.edu:10230/48031
network_acronym_str ES
network_name_str España
repository_id_str
spelling Inflammatory response of ischemic tolerance in circulating plasma: preconditioning-induced by transient ischemic attack (TIA) phenomena in acute ischemia patients (AIS)Colàs-Campàs, LauraFarré, JoanMauri Capdevila, GerardMolina-Seguín, JessicaAymerich, NúriaOis Santiago, Angel JavierRoquer, JaumeTur, SilviaGarcía-Carreira, María Del CarmenMartí-Fàbregas, JoanCruz-Culebras, AntonioSegura, TomásArqué, GloriaPurroy, FranciscoBiomarker (BM)Endogenous neuroprotectionIschemic preconditioning (IPC)Ischemic strokePlasmaTransient ischemic attack (TIA)Neuromuscular diseases care in the era of COVID-19Introduction: Ischemic tolerance (IT) refers to a state where cells are resistant to the damaging effects caused by periods of ischemia. In a clinical scenario, the IT phenomenon would be activated by a recent transient ischemic attack (TIA) before an ischemic stroke (IS). The characterization of inflammatory protein expression patterns will contribute to improved understanding of IT. Methods: A total of 477 IS patients from nine hospitals, recruited between January 2011 and January 2016, were included in the current study and divided in three groups: 438 (91.9%) patients without previous TIA (group 1), 22 (4.6%) patients who suffered TIA 24 h before IS (group 2), and 17 (3.5%) patients who suffered TIA between 24 h and 7 days prior to IS (group 3). An inflammatory biomarker panel (IL-6, NT-proBNP, hsCRP, hs-Troponin, NSE, and S-100b) on plasma and a cytokine antibody array was performed to achieve the preconditioning signature potentially induced by TIA phenomena. Primary outcome was modified rankin scale (mRs) score at 90 days. Results: Recent previous TIA was associated with better clinical outcome at 90 days (median mRS of group 1: 2.0 [1.0-4.0]; group 2: 2.0 [0.0-3.0]; group 3: 1.0 [0-2.5]; p = 0.086) and smaller brain lesion (group 1: 3.7 [0.7-18.3]; group 2: 0.8 [0.3-8.9]; group 3: 0.6 [0.1-5.5] mL; p = 0.006). All inflammation biomarkers were down regulated in the groups of recent TIA prior to IS compared to those who did not suffer a TIA events. Moreover, a cytokine antibody array revealed 30 differentially expressed proteins between the three groups. Among them, HRG1-alpha (Fold change 74.4 between group 1 and 2; 74.2 between group 1 and 3) and MAC-1 (Fold change 0.05 between group 1 and 2; 0.06 between group 1 and 3) expression levels would better stratify patients with TIA 7 days before IS. These two proteins showed an earlier inflammation profile that was not detectable by the biomarker panel. Conclusion: Inflammatory pathways were activated by transient ischemic attack, however the period of time between this event and a further ischemic stroke could be determined by a protein signature that would contribute to define the role of ischemic tolerance induced by TIA.Frontiers202120212020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/48031http://dx.doi.org/10.3389/fneur.2020.552470reponame:Repositorio Digital de la UPFinstname:Universitat Pompeu FabraInglésCopyright © 2020 Colàs-Campàs, Farre, Mauri-Capdevila, Molina-Seguín, Aymerich, Ois, Roquer, Tur, García-Carreira, Martí-Fàbregas, Cruz-Culebras, Segura, Arque and Purroy. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). http://creativecommons.org/licenses/by/4.0/. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.http://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repositori.upf.edu:10230/480312026-06-12T07:21:37Z
dc.title.none.fl_str_mv Inflammatory response of ischemic tolerance in circulating plasma: preconditioning-induced by transient ischemic attack (TIA) phenomena in acute ischemia patients (AIS)
title Inflammatory response of ischemic tolerance in circulating plasma: preconditioning-induced by transient ischemic attack (TIA) phenomena in acute ischemia patients (AIS)
spellingShingle Inflammatory response of ischemic tolerance in circulating plasma: preconditioning-induced by transient ischemic attack (TIA) phenomena in acute ischemia patients (AIS)
Colàs-Campàs, Laura
Biomarker (BM)
Endogenous neuroprotection
Ischemic preconditioning (IPC)
Ischemic stroke
Plasma
Transient ischemic attack (TIA)
Neuromuscular diseases care in the era of COVID-19
title_short Inflammatory response of ischemic tolerance in circulating plasma: preconditioning-induced by transient ischemic attack (TIA) phenomena in acute ischemia patients (AIS)
title_full Inflammatory response of ischemic tolerance in circulating plasma: preconditioning-induced by transient ischemic attack (TIA) phenomena in acute ischemia patients (AIS)
title_fullStr Inflammatory response of ischemic tolerance in circulating plasma: preconditioning-induced by transient ischemic attack (TIA) phenomena in acute ischemia patients (AIS)
title_full_unstemmed Inflammatory response of ischemic tolerance in circulating plasma: preconditioning-induced by transient ischemic attack (TIA) phenomena in acute ischemia patients (AIS)
title_sort Inflammatory response of ischemic tolerance in circulating plasma: preconditioning-induced by transient ischemic attack (TIA) phenomena in acute ischemia patients (AIS)
dc.creator.none.fl_str_mv Colàs-Campàs, Laura
Farré, Joan
Mauri Capdevila, Gerard
Molina-Seguín, Jessica
Aymerich, Núria
Ois Santiago, Angel Javier
Roquer, Jaume
Tur, Silvia
García-Carreira, María Del Carmen
Martí-Fàbregas, Joan
Cruz-Culebras, Antonio
Segura, Tomás
Arqué, Gloria
Purroy, Francisco
author Colàs-Campàs, Laura
author_facet Colàs-Campàs, Laura
Farré, Joan
Mauri Capdevila, Gerard
Molina-Seguín, Jessica
Aymerich, Núria
Ois Santiago, Angel Javier
Roquer, Jaume
Tur, Silvia
García-Carreira, María Del Carmen
Martí-Fàbregas, Joan
Cruz-Culebras, Antonio
Segura, Tomás
Arqué, Gloria
Purroy, Francisco
author_role author
author2 Farré, Joan
Mauri Capdevila, Gerard
Molina-Seguín, Jessica
Aymerich, Núria
Ois Santiago, Angel Javier
Roquer, Jaume
Tur, Silvia
García-Carreira, María Del Carmen
Martí-Fàbregas, Joan
Cruz-Culebras, Antonio
Segura, Tomás
Arqué, Gloria
Purroy, Francisco
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Biomarker (BM)
Endogenous neuroprotection
Ischemic preconditioning (IPC)
Ischemic stroke
Plasma
Transient ischemic attack (TIA)
Neuromuscular diseases care in the era of COVID-19
topic Biomarker (BM)
Endogenous neuroprotection
Ischemic preconditioning (IPC)
Ischemic stroke
Plasma
Transient ischemic attack (TIA)
Neuromuscular diseases care in the era of COVID-19
description Introduction: Ischemic tolerance (IT) refers to a state where cells are resistant to the damaging effects caused by periods of ischemia. In a clinical scenario, the IT phenomenon would be activated by a recent transient ischemic attack (TIA) before an ischemic stroke (IS). The characterization of inflammatory protein expression patterns will contribute to improved understanding of IT. Methods: A total of 477 IS patients from nine hospitals, recruited between January 2011 and January 2016, were included in the current study and divided in three groups: 438 (91.9%) patients without previous TIA (group 1), 22 (4.6%) patients who suffered TIA 24 h before IS (group 2), and 17 (3.5%) patients who suffered TIA between 24 h and 7 days prior to IS (group 3). An inflammatory biomarker panel (IL-6, NT-proBNP, hsCRP, hs-Troponin, NSE, and S-100b) on plasma and a cytokine antibody array was performed to achieve the preconditioning signature potentially induced by TIA phenomena. Primary outcome was modified rankin scale (mRs) score at 90 days. Results: Recent previous TIA was associated with better clinical outcome at 90 days (median mRS of group 1: 2.0 [1.0-4.0]; group 2: 2.0 [0.0-3.0]; group 3: 1.0 [0-2.5]; p = 0.086) and smaller brain lesion (group 1: 3.7 [0.7-18.3]; group 2: 0.8 [0.3-8.9]; group 3: 0.6 [0.1-5.5] mL; p = 0.006). All inflammation biomarkers were down regulated in the groups of recent TIA prior to IS compared to those who did not suffer a TIA events. Moreover, a cytokine antibody array revealed 30 differentially expressed proteins between the three groups. Among them, HRG1-alpha (Fold change 74.4 between group 1 and 2; 74.2 between group 1 and 3) and MAC-1 (Fold change 0.05 between group 1 and 2; 0.06 between group 1 and 3) expression levels would better stratify patients with TIA 7 days before IS. These two proteins showed an earlier inflammation profile that was not detectable by the biomarker panel. Conclusion: Inflammatory pathways were activated by transient ischemic attack, however the period of time between this event and a further ischemic stroke could be determined by a protein signature that would contribute to define the role of ischemic tolerance induced by TIA.
publishDate 2020
dc.date.none.fl_str_mv 2020
2021
2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/48031
http://dx.doi.org/10.3389/fneur.2020.552470
url http://hdl.handle.net/10230/48031
http://dx.doi.org/10.3389/fneur.2020.552470
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Frontiers
publisher.none.fl_str_mv Frontiers
dc.source.none.fl_str_mv reponame:Repositorio Digital de la UPF
instname:Universitat Pompeu Fabra
instname_str Universitat Pompeu Fabra
reponame_str Repositorio Digital de la UPF
collection Repositorio Digital de la UPF
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869415436830900224
score 15.81155

Similares en LA Referencia